NATURE’S SUNSHINE PRODUCTS, INC. Restructuring and Related Cost, Incurred Cost
NATURE’S SUNSHINE PRODUCTS, INC. (NATR) reported Restructuring and Related Cost, Incurred Cost of $500.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostIncurredCost · last filed 2018-05-10
- NATURE’S SUNSHINE PRODUCTS, INC. restructuring and related cost, incurred cost for the quarter ending 2018-03-31 was $500.00K, a 37.50% decline year-over-year.
- NATURE’S SUNSHINE PRODUCTS, INC. restructuring and related cost, incurred cost for the quarter ending 2017-03-31 was $800.00K.
| Period end | Restructuring and Related Cost, Incurred Cost 3 month |
|---|---|
| 2018-03-31 | $500.00K 10-Q · filed 2018-05-10 |
| 2017-03-31 | $800.00K 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |